Where do these guests come from? A diagnostic approach for metastatic lymph nodes.
Lymph node metastasis is the most common mode for the spread of carcinomas and solid tumors, such as malignant melanoma (1). Although many radiological and scintigraphy methods were being used for the diagnosis of solid tumors, an excisional biopsy of metastatic lymph nodes can still be necessary especially for oncological treatment procedures (2). In addition, some of the primary tumors presented with lymphadenopathies (LAP) could not be located by imaging. Moreover, the primary foci of malignant melanoma and germ cell tumors can be burnout tumors, which can only be diagnosed by an excisional biopsy of the involved lymph nodes.
Metastatic lymph nodes usually present as palpable masses but can be found by physical examination or imaging studies of patients by investigating for various symptoms (2). In asymptomatic cases, palpable LAP is generally very striking for both clinicians and patients and allows systemic evaluations. However, an excisional biopsy of these enlarged lymph nodes can also be a diagnostic approach for uncertain imaging results.
In this study, we aimed to assess the nonhematological malignancies presenting with LAP and reveal the histopathological approach for the diagnosis of the primary focus.
MATERIAL AND METHODS
All lymph node excisional biopsies (n=632) performed between January 2013 and June 2016 were assessed retrospectively. Every case was investigated for the diagnosis of a known primary focus from hospital records and medical history. Patients with known solid primaries and lymph node metastases diagnosed synchronously with the primary tumor (n=144) were excluded. Cases presenting with lymph node enlargement and diagnosed as any form of hematological malignancies (n=109) or any form of reactive hyperplasia (n=310) and specific infections (n=48) were also excluded. The demographic features and localizations of the lymph nodes were obtained from pathology reports.
Cases with palpable masses were examined by the applied clinicians, and first-step radiologic tests, such as X-ray, ultrasonography (USG), and mammography, were performed; in cases where no explanatory result was found for lymph node enlargement, an excisional biopsy was offered to the patients.
The indications of lymph node excision determined by the clinicians were as follows:
* Primary tumor not assessed using physical examination and first-step imaging studies (X-ray, USG, or mammography)
* Negative biopsies from possible primaries
* Suspicious cases for hematological or nonhematological malignancies
None of the patients underwent positron emission tomography/computerized tomography (PET/CT) before the excision of the enlarged lymph nodes.
Cases diagnosed as reactive LAP or hematological malignancies in addition to patients treated at another center or unavailable for follow up were excluded. Written informed consent was obtained from patients before the operation who participated in this study.
The hematoxylin-eosin stained slides of excisional biopsies were examined in addition to the slides analyzed by immunohistochemistry (IHC). All cases were immunohistochemically analyzed using the (Leica Bond Max[R], Leica Biosystems, Germany) automated staining procedure. Antibodies used for IHC analysis was chosen systematically according to the morphological appearance of the entities encountered in the pathological differential diagnosis. The final diagnosis was provided according to histopathological and IHC results followed by a confirmation of the primaries using radiological methods.
A total of 21 cases diagnosed with nonhematological solid tumor presented as lymph node enlargement between January 2013 and June 2016 were assessed retrospectively. The mean age was 57.23 y (range, 33-92 y), and 12 patients were males and 9 were females.
The localizations of the enlarged lymph nodes were inguinal (8 cases), axillary (6 cases), cervical (4 cases), and supraclavicular (3 cases). All patients applied with palpable mass, except 2 cases that were presented with inguinal pain and were diagnosed as prostatic adenocarcinoma and renal cell carcinoma.
All of the female patients (n=9) were assessed by breast and axillary examination followed by mammography and breast USG as the first step in the diagnostic approach. Male patients with axillary lymph node enlargement (n=2) were also examined using breast USG. Additionally, 3 cases were reported as those of metastatic epithelial tumor using fine needle aspiration cytology followed by the excision of the involved lymph node, and the final tumor type was evaluated by a histopathological assessment. None of the cases were diagnosed before the excision of the lymph node. No sarcomatous tumor was found among all the metastatic lymph nodes.
Histopathological Evaluation and IHC Analysis
The most common metastatic tumor presented with LAP was malignant melanoma (n=6; Figure 1a and 1b), followed by breast carcinoma (n=4; Figure 1c and 1d), squamous cell carcinoma (SCC; n=2), and ovarian carcinoma (n=2). Other metastatic tumors were urothelial carcinoma (Figure 1e and 1f), papillary thyroid carcinoma (Figure 1g and 1h), renal cell carcinoma, prostatic adenocarcinoma, endometrial adenocarcinoma, and germ cell tumor (n=2).
Malignant melanoma as the most common metastatic tumor metastasized to axillary (n=2), cervical (n=2), inguinal (n=1), and supraclavicular (n=1) lymph nodes. Other tumors and involved lymph nodes are given in Table 1. Histopathological characteristics and IHC features are summarized in Table 2. Frequencies and descriptive statistics were done by SPSS software v20, IBM, USA.
Clinical Evaluation and Radiological Findings After Histopathological Diagnosis
None of the cases diagnosed with metastatic melanoma underwent detailed dermatological examination. After the diagnosis, only one case had a scalp lesion and the excision of the lesion showed melanoma with a Clark level of IV and a Breslow thickness of 2.4 cm. Other metastatic melanoma cases had no primary foci and were accepted as burnout primaries.
None of the female patients with axillary lymph nodes had any breast lesion detected by USG and mammography before the excision. After the diagnosis, all metastatic breast carcinoma cases had breast magnetic resonance imaging (MRI) and mammarian masses were detected with sizes in the range of 1.2-1.8 cm.
The cases with SCC had high-resolution lung CT and/or PET/CT for detecting the primary foci. One of the cases had shown lung primary and the other case had a 5 cm mass located in the renal pelvis biopsied using ureterorenoscopy and diagnosed as high-grade urothelial carcinoma with extensive squamous differentiation.
Metastatic ovarian carcinomas showed bilateral lobulated, contrasted cystic masses with sizes of 23x34 mm and 46x61 mm in the ovarian region on PET/CT. After the operation, the final diagnosis was ovarian serous carcinoma. Another case presented with axillary lymph node involvement had negative results in mammography and breast MRI, and the excision of the lymph node was performed with a suspicion of hematological malignancy. However, after the diagnosis of metastasis, the PET/CT showed a heterogenous cystic lesion of 5.5 cm size in the left ovarian region and extensive intra-abdominal metastatic lymph nodes, and the diagnosis was confirmed after the operation as ovarian high-grade serous carcinoma.
A 50-year-old female patient with axillary metastasis was investigated using mammography and breast USG; however, no mass was detected. After the excision of the lymph node with a suspicion of metastasis of occult breast carcinoma, the final diagnosis was of metastatic ovarian serous carcinoma. The diagnosis was confirmed by lower abdominal CT showing left ovarian cystic mass, which was operated and diagnosed as ovarian serous carcinoma with a size of 44x32 mm and having a thin septae.
The case of metastatic urothelial carcinoma was then confirmed by cystoscopic samples of highgrade urothelial carcinoma with muscularis propria and extensive urothelial carcinoma in situ.
The case of papillary thyroid carcinoma was examined using USG and diagnosed as multinodular goiter with a maximum size of the nodule as 1.2 cm. The fine needle aspiration biopsy (FNAB) performed upon both the thyroid and the lymph node was benign, and the lymph node was subsequently excised. After the diagnosis of the metastatic lymph node, total thyroidectomy was performed and papillary carcinoma was diagnosed at three different foci with a maximum size of 1.2 cm showing capsular invasion. The case applied with inguinal pain was operated for inguinal hernia, and an enlarged lymph node was detected during the operation. After the diagnosis of metastatic prostatic adenocarcinoma, rectal examination revealed enlarged, hard prostatic tissue with a slight increase of prostatespecific antigen (PSA; 4.7 ng/mL).
A 38-year-old male applied with inguinal pain, and the enlarged inguinal lymph node was excised because of the suspicion of a hematological malignancy. After the diagnosis of metastatic renal cell carcinoma, detailed imaging studies revealed a cortical, 3.8 cm-sized, solid renal mass located in the upper lobe of the right kidney. After radical nephrectomy, a clear cell renal cell carcinoma of Fuhrmann grade 3 with vascular invasion was detected.
In one of the 2 cases of metastatic germ cell tumor, a 2.4 cmsized mixed germ cell testicular tumor (seminoma, 70%; embryonal carcinoma, 30%) with necrosis was detected through orchiectomy. The other case showed a fibrohyalinized nodule located in the right testis with no alive tumor cells. The morphological features were concordant with burnout tumor.
Nonhematological malignancies presenting with lymph node enlargement are one of the most confusing cases for clinicians. A standard diagnostic approach for enlarged lymph nodes should consider detailed medical history, physical examination, clinical symptoms and findings, laboratory and imaging studies, and histopathological evaluation using IHC analysis (2).
Radiological studies have diagnostic limitations of about 30%-50% for various tumor types (3). However, MRI has a chance of tumor detection of about 70% in axillary metastasis (4). Fluorodeoxyglucose (FDG) PET, which has an important role in investigating metastasis of malign tumors, has various detection rates in primary unknown tumors (PUT) with the most common being lung (5) and head and neck cancers of about 50%. There are studies supporting that FDG PET/CT is better in detecting primary tumors. In a study, a rate of 55% was reported for FDG PET/CT, whereas 31% for FDG PET in cervical lymph node enlarged patients (6, 7). In another metaanalysis, the detection rate of FDG PET/CT was 37% with the most common primary being lung (33%) (8). In another study, 28.5% of metastatic cases were unable to locate the primary foci using FDG PT/CT (9). In some centers, otorhinolaryngologists particularly use routine PET/CT for lymph node enlargements in the head and neck region (10).
The limitations of radiological methods redirect clinicians to pathological evaluation. Because many different targeted drugs were being used for different tumor types, finding the exact primary focus of the metastatic tumors is necessary in oncology practice. One of the most definitive results may be accomplished by a histological examination.
The histopathological assessment of excisional lymph node biopsies is cost effective in patients with metastatic lymph nodes and who were being investigated for primary tumors. In these patients, the tumor can only be diagnosed by the histopathological evaluation of the enlarged lymph node, which also excludes hematological malignancies (11). These excisional biopsies may be the only way for determining treatment protocols and prevent patients from more invasive procedures.
Tru-cut, incisional, or open biopsy can provide material for histopathological evaluation; however, total excision of the lymph node with intact capsule is the gold standard for pathological analysis (1). FNAB is relatively useful for epithelial tumors, but excisional biopsies are more important as they enable better samples for tumor morphology as well as IHC and histochemical analysis (12). As epithelial tumors metastasize lymph nodes from subcapsular sinuses, total excision with intact capsule is much more important for pathological evaluation. However, lymph node excision is a procedure and we know that every operation has its own risks due to anesthesia or the procedure itself. Therefore, the decision for lymph node excision should be considered based on all the aspects of the patient.
As the most common subtypes of PUT are unspecified adenocarcinomas, undifferentiated adenocarcinomas, and poorly-differentiated tumors, it is very important to specify the primary focus of the metastatic disease. The general pathological algorithmic approach for differentiating metastasis is to decide whether the tumor is epithelial, lymphoid, sarcomatous, or melanoma. Although there is no worldwide accepted guidelines for pathological analysis, it is commonly advisable to start with vimentin, Cluster of Differentiation (CD) 45, HMB-45, and pancytokeratin (2, 13, 14). Many and different antibodies can be used for IHC; however, sometimes overlapping results may complicate suggestions for primary tumors. In cases with a general impact of epithelial tumor metastasis, CK 7 and CK 20 may be chosen as the first step (15). In all of our cases, the diagnostic approach was initiated with pancytokeratin, vimentin, and CD45 to decide the nature of the tumor.
Antibodies specific for an organ or a tumor type can be added due to histological findings (such as PLAP and OCT 3/4 for germ cell tumors; chromogranin A, synaptophysin, and CD 56 for neuroendocrine tumors; PSA and PSAP for prostatic origin; mammoglobin and GCDFP-15 for breast origin; CDX2 for intestinal origin; WT1 and CA-125 for ovarian cancers; TTF-1 for lung and thyroid cancer; and thyroglobulin for thyroid origin). Despite the fact that all tumor types may not have a definite specific antibody, IHC analysis is advantageous among many imaging methods due to its cost-effectiveness (2, 12, 16). We also used specific antibodies, such as thyroglobulin, CA125, CD X2, WT1, and GCDFP15, for detecting the primary foci.
The necessity for molecular diagnostic methods cannot be denied because gene expression profiles have an important role in tumor classification according to literature (17, 18) However, the accessibility to gene profiling methods can be impossible for small scale hospitals and this impossibility increases the importance of histopathological evaluation and IHC analysis of the excisional biopsies in especially small centers.
Even by using many diagnostic modalities, some of the metastatic cases remain as primary unknown tumors, forming the fourth most common cause of death (1).
The first-step diagnostic approach must include IHC markers that may help to decide if the tumor is epithelial, sarcomatous, lymphoid, or melanoma. In cases of melanoma and germ cell tumors, it is important to remember that the primary tumor can be "burnout". The diagnosis of the primary tumor from the histopathological evaluation is important for clinical, prognostic, and treatment protocols especially for tumors of which primary focus can be regressed spontaneously. As observed from our results, melanoma is the most common metastatic tumor with unknown primary focus. In 6 cases (28.5%), melanoma was diagnosed due to its metastasis.
Molecular DNA profile studies added to pathological evaluation increases the diagnostic rate up to 80%. However, the high cost and inapplicability of molecular studies at every center emphasize the accessibility and cost effectiveness of routine pathological examination and IHC analysis.
Nonhematological malignancies presenting with LAP are one of the most complicated cases for clinicians. In cases presenting with LAP without a primary focus found by simple radiological methods, the primary tumor can be diagnosed by a histopathological evaluation of the metastatic lymph nodes. The histopathological evaluation of the excisional metastatic lymph node biopsies is an important method due to cost effectiveness and easy applicability.
Ethics Committee Approval: Not required in this study.
Informed Consent: Written informed consent was obtained from patients who participated in this study.
Peer-review: Externally peer-reviewed.
Author Contributions: Concept - Y.D., S.E., V.K.; Design - Y.D., O.I.C., S.Y.C.; Supervision - O.D., S.Y.C.; Resource - Y.D., O.D., V.K.; Materials - V.K., O.D.; Data Collection and/or Processing - Y.D., O.D., S.E., V.K., O.I.C., S.Y.C.; Analysis and/or Interpretation - Y.D., S.E., S.Y.C., O.I.C.; Literature Search - O.D., V.K., S.Y.C.; Writing Manuscript - Y.D., O.I.C., S.Y.C., S.E.; Critical Reviews - V.K., O.I.C., S.Y.C.; Other - Y.D., S.E., O.D.
Conflict of Interest: The authors have no conflicts of interest to declare.
Financial Disclosure: The authors declared that this study has received no financial support.
(1.) Krementz ET, Cerise EJ, Foster DS, Morgan LR Jr. Metastases of undetermined source. Curr Probl Cancer 1979; 4: 4-37. [CrossRef]
(2.) Natoli C, Ramazzotti V, Nappi O, Giacomini P, Palmeri S, Salvatore M et al. Unknown primary tumors: Review. Biochimica et Biophysica Acta 2011; 1816: 13-24. [CrossRef]
(3.) Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumours of unknown primary origin. J Clin Oncol 1995; 13: 2094-103. [CrossRef]
(4.) Orel SG, Weinstein SP, Schnall MD, Reynolds CA, Schuchter LM, Fraker DL et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancies. Radiology 1999; 212: 543-549. [CrossRef]
(5.) Seve P, Billotey C, Broussolle C, Dumontet C, Mackey JR. The role of 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007; 109: 292-299. [CrossRef]
(6.) Lassen U, Daugaard G, Eigtved A, Damgaard K, Friberg L. 18FFDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 1999;35: 1076-1082. [CrossRef]
(7.) Rades D, Kuhnel G, Wildfang I, Borner AR, Schmoll HJ, Knapp W.Localised disease in can- cer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 2001; 12: 1605-1609. [CrossRef]
(8.) Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol 2009; 19: 731-744. [CrossRef]
(9.) Simsek F, Entok E. Primeri Bilinmeyen Kanserlerde Primer Odak Tespitinde PET/BT'nin Etkinligi. Firat Med J 2015; 20: 33-36.
(10.) Basal Y, Eryilmaz A. Primeri Bilinmeyen Boyun Metastazlarina Guncel Yaklasim. Van Tip Derg 2016; 23: 294-300.
(11.) Schapira DV, Jarrett AR. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med 1995; 155: 2050-2054. [CrossRef]
(12.) Mottolese M, Venturo I, Salzano M, Benevolo M, Bigotti A, Natali PG. Immunocytodiagnosis of solid tumors employing panels of monoclonal antibodies. J Clin Lab Anal 1993; 7: 238-242. [CrossRef]
(13.) Greco FA, Hainsworth JD. Poorlydifferentiatedcarcinoma (with or without features of adenocarcinoma) of unknown primary site. Adenocarcinoma of unknown primary site. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer Principles & Practice of Oncology: Cancer of Unknown Primary Site. 7th ed. Philedelphia: Lipincott Williams & Wilkins; 2005. p. 2216-22.
(14.) Adams H, Schmid P, Dirnhofer S, Tzankov A. Cytokeratin expression in hematological neoplasms: a tissue microarray study on 866 lymphoma and leukemia cases. Pathol Res Pract 2008; 204: 569-573. [CrossRef]
(15.) Vang R, Gown AM, Wu LS, Barry TS, Wheeler DT, Yemelyanova A et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 2006; 19: 1421-1428. [CrossRef]
(16.) Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005; 11: 3766-3772. [CrossRef]
(17.) Pilarsky CP, Schmitt AO, Dahl E, Rosenthal A. Microarrays--chances and challenges. Curr Opin Mol Ther 1999; 1: 727-736.
(18.) Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 2007; 43: 2026-4036.[CrossRef]
Yelda Dere (1) [iD], Sumeyye Ekmekci (2) [iD], Serkan Celik (1) [iD], Ozgur Ilhan Celik (1) [iD], Ozcan Dere (3) [iD], Volkan Karakus (4) [iD]
ORCID IDs of the authors:
Y.D. 0000-0003-0238-2236; S.E.0000-0003-1607-500X; S.C. 0000-0002-8710-7710; O.I.C. 0000-0002-3549-822X; O.D. 0000-0002-5589-4326; V.K. 0000-0001-9178-2850.
Cite this paper as:
Dere Y, Ekmekci S, Celik S, Celik OI, Dere O, Karakus V. Where do these guests come from? A diagnostic approach for metastatic lymph nodes. Turk J Surg 2018; 34: 131-136.
(1) Department of Pathology, Mugla Sitki Kocman University School of Medicine, Mugla, Turkey
(2) Department of Pathology, Tepecik Training and Research Hospital, Izmir, Turkey
(3) Department of General Surgery, Mugla Sitki Kocman University School of Medicine, Mugla, Turkey
(4) Department of Hematology, Mugla Sitki Kocman Training and Research Hospital, Mugla, Turkey
[c]Copyright 2018 by Turkish Surgical Association
Table 1. Characteristics of metastatic lymph nodes Age (y) Sex Localization Symptom 79 Male Supraclavicular Palpable mass 64 Male Supraclavicular Palpable mass 33 Male Axillary Palpable mass 63 Male Cervical Palpable mass 62 Male Supraclavicular Palpable mass 76 Male Axillary Palpable mass 42 Male Inguinal Palpable mass 50 Male Inguinal Palpable mass 38 Male Inguinal Inguinal pain 78 Male Inguinal Inguinal pain 86 Male Inguinal Palpable mass 45 Male Inguinal Palpable mass 34 Female Axillary Palpable mass 92 Female Axillary Palpable mass 41 Female Cervical Palpable mass 62 Female Inguinal Palpable mass 40 Female Cervical Palpable mass 63 Female Inguinal Palpable mass 56 Female Axillary Palpable mass 36 Female Axillary Palpable mass 62 Female Cervical Palpable mass Age (y) Diagnosed primary 79 Squamous cell carcinoma 64 Squamous cell carcinoma 33 Malignant melanoma 63 Malignant melanoma 62 Malignant melanoma 76 Malignant melanoma 42 Germ cell tumor 50 Malignant melanoma 38 Renal cell carcinoma 78 Prostate adenocarcinoma 86 Urothelial carcinoma 45 Germ cell tumor 34 Breast carcinoma 92 Breast carcinoma 41 Breast carcinoma 62 Endometrial adenocarcinoma 40 Malignant melanoma 63 Ovarian serous carcinoma 56 Ovarian serous carcinoma 36 Breast carcinoma 62 Papillary thyroid carcinoma Table 2. Histopathological and immunohistochemical features of the metastatic tumors Primary tumor Histological features Melanoma Tumoral nests of cells with conspicuous nucleoli and numerous mitotic fgures Breast carcinoma Tubules and solid tumoral areas Squamous cell carcinoma Tumoral squamous cell nests with keratinization and keratin pearls Prostatic adenocarcinoma Cribriform malignant glandular structures Papillary thyroid carcinoma Tumoral cells showing papillary confguration with ground glass nuclei, nuclear grooves, and overlap Ovarian carcinoma Tubular, adenoid, and papillary confguration of pleomorphic tumoral cells showing conspicuous nucleoli Renal cell carcinoma Tumoral cell nests with clear cytoplasm and conspicuous nucleoli Germ cell tumors Cords and sheets of uniform but malignant cells surrounded with lymphocytic infiltration Endometrioid Epitheloid tumor characterized by solid adenocarcinoma sheets of round cells showing prominent nucleoli Urothelial carcinoma Tumoral cords and columns with cells showing conspicuous nucleoli and hyperchromatic nuclei Primary tumor IHC features Melanoma HMB-45(+), S100 (+) Breast carcinoma GCDFP-15 (+), CK 7(+), ER/PR (+) Squamous cell carcinoma p63(+), HMWCK(+), CK20(-), TTF-1(-) Prostatic adenocarcinoma PSA (+),AMACR(+), CDX2(-) Papillary thyroid carcinoma TTF-1(+), CK7(+), Thyroglobuline (+) Ovarian carcinoma CK7 (+), WT1 (+), CA125 (+), CK20 (-), TTF-1 (-), CDX2 (-), GCDFP-15 (-) Renal cell carcinoma EMA (+), CD10 (+), Vimentin (+), PAX8 (+), CK7 (-), PSA (-), CDX2 (-) Germ cell tumors OCT 3/4 (+), CD117 (+), PLAP (+) Endometrioid pan CK (+), Vimentin (-), ER (+) adenocarcinoma Urothelial carcinoma CK 20 (+), GATA3 (+), Uroplakin III (+), CK7 (-), HMB45 (-), PSA (-), TTF-1 (-), OCT 3/4 (-), CDX2 (-) Primary tumor Additional parameters Melanoma Melanin pigment (+) Breast carcinoma - Squamous cell carcinoma - Prostatic adenocarcinoma Gleason score 4+4 (Grade group 4) Papillary thyroid carcinoma - Ovarian carcinoma - Renal cell carcinoma - Germ cell tumors - Endometrioid - adenocarcinoma Urothelial carcinoma - HMB45: Human melanoma black-45; GCFDP-15:Gross cystic disease fluid protein-15; CK7: cytokeratin 7; ER: estrogen receptor; PR: progesterone receptor; HMWCK: high molecular weight cytokeratin; CK20: Cytokeratin 20; TTF-1: thyroid transcription factor-1; PSA: prostate specific antigen; AMACR: Alpha-methyl CoA Racemase; CDX2: Cluster of differentiation X2; WT1: Wilms tumor 1; CA 125: cancer antigen 125; EMA: epithelial membrane antigen; CD 10: Cluster of differentiation 10; PAX 8: Paired box gene 8; OCT 3/4: octamer-binding transcription factor 3/4; CD117: Cluster of differentiation 117; PLAP : placental alcaline phosphatase; Pan CK: pancytokeratin; GATA 3: GATA Binding Protein 3
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Original Article|
|Author:||Dere, Yelda; Ekmekci, Sumeyye; Celik, Serkan; Celik, Ozgur Ilhan; Dere, Ozcan; Karakus, Volkan|
|Publication:||Turkish Journal of Surgery|
|Date:||Jun 1, 2018|
|Previous Article:||Survival outcomes after D1 and D2 lymphadenectomy with R0 resection in stage II-III gastric cancer: Longitudinal follow-up in a single center.|
|Next Article:||Missed thyroid gland after total thyroidectomy.|